Omeros (OMER) to Release Quarterly Earnings on Monday

Omeros (NASDAQ:OMER) will likely be announcing its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

Omeros Stock Performance

Omeros stock opened at $8.47 on Monday. The company has a market cap of $490.84 million, a price-to-earnings ratio of -3.67 and a beta of 2.03. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60. The firm has a 50 day moving average price of $8.69 and a 200 day moving average price of $7.55.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Friday, January 17th. D. Boral Capital reissued a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Friday, March 21st. Finally, StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Omeros presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.